Oncotarget

Research Papers:

Sustained-releasing hollow microparticles with dual-anticancer drugs elicit greater shrinkage of tumor spheroids

Jong-Suep Baek, Chee Chong Choo, Nguan Soon Tan and Say Chye Joachim Loo _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:80841-80852. https://doi.org/10.18632/oncotarget.20591

Metrics: PDF 837 views  |   HTML 2021 views  |   ?  


Abstract

Jong-Suep Baek1, Chee Chong Choo2, Nguan Soon Tan2,3,4,5 and Say Chye Joachim Loo1,6

1School of Materials Science and Engineering, Nanyang Technological University, 639798, Singapore

2School of Biological Sciences, Nanyang Technological University, 637551, Singapore

3Lee Kong Chian School of Medicine, Nanyang Technological University, 639798, Singapore

4Institute of Molecular Cell Biology, Proteos, Agency for Science Technology and Research, 138673, Singapore

5KK Research Centre, KK Women’s and Children Hospital, 229899, Singapore

6Singapore Centre on Environmental Life Sciences Engineering, Nanyang Technological University, 637551, Singapore

Correspondence to:

Say Chye Joachim Loo, email: joachimloo@ntu.edu.sg

Keywords: microparticles, controlled-release, PLGA, combination therapy, paclitaxel

Received: July 19, 2017    Accepted: August 04, 2017    Published: August 24, 2017

ABSTRACT

Polymeric particulate delivery systems are vastly explored for the delivery of chemotherapeutic agents. However, the preparation of polymeric particulate systems with the capability of providing sustained release of two or more drugs is still a challenge. Herein, poly (D,L-lactic-co-glycolic acid, 50:50) hollow microparticles co-loaded with doxorubicin and paclitaxel were developed through double-emulsion solvent evaporation technique. Hollow microparticles were formed through the addition of an osmolyte into the fabrication process. The benefits of hollow over solid microparticles were found to be higher encapsulation efficiency and a more rapid drug release rate. Further modification of the hollow microparticles was accomplished through the introduction of methyl-β-cyclodextrin. With this, a higher encapsulation efficiency of both drugs and an enhanced cumulative release were achieved. Spheroid study further demonstrated that the controlled release of the drugs from the methyl-β-cyclodextrin -loaded hollow microparticles exhibited enhanced tumor regressions of MCF-7 tumor spheroids. Such hollow dual-drug-loaded hollow microparticles with sustained releasing capabilities may have a potential for future applications in cancer therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20591